The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical application of circulating tumor DNA (ctDNA) in patients with metastatic gastric cancer.
 
Moonki Hong
No Relationships to Disclose
 
Kwang Seob Lee
No Relationships to Disclose
 
Sejung Park
No Relationships to Disclose
 
Kyoo Hyun Kim
No Relationships to Disclose
 
Hyunwook Kim
No Relationships to Disclose
 
Jingmin Che
No Relationships to Disclose
 
Woo Sun Kwon
No Relationships to Disclose
 
Choong-kun Lee
Honoraria - Boryung; Dong-A ST; Novartis; SERVIER
Consulting or Advisory Role - AstraZeneca
 
Minkyu Jung
Employment - Ensol Biosciences (I)
Stock and Other Ownership Interests - Ensol Biosciences; Ensol Biosciences (I)
Honoraria - Celltrion; Lilly
 
Hyun Cheol Cheol Chung
Employment - MDBiolab
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Saeam Shin
No Relationships to Disclose
 
Seung-Tae Lee
Leadership - Dxome
 
Jong Rak Choi
Leadership - Dxome
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Eutilex; Indivumed; LG Chem; MSD Oncology; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly; MedPacto; MSD Oncology; Roche/Genentech; SillaJen